Company News 

Significant vote of confidence for OXB

Significant vote of confidence for OXB

Shares in Oxford Biomedica (OXB) saw a double-digit rise after Danish life sciences investment group Novo Holdings A/S bought a 10 per cent stake in the gene/cell therapy group for £53.5m. The proceeds will be used to repay the existing debt facility with Oaktree Capital Management and to further develop the LentiVector platform and the proprietary product portfolio.Novo Holdings has agreed to subscribe for 6.57m new ordinary shares in OXB. 

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now